Videos

Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.

Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."

At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.

Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"

At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."

Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."

At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss visual snow syndrome and whether it should be evaluated during standard in-clinic ophthalmologic testing.

After a brief hiatus during the pandemic, the Flying Eye Hospital program returns.

Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.

At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.

Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.

Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.

Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.

Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.

Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Tocilizumab and the influence it can have on ophthalmic outcomes in giant cell arteritis.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, talk about the potential cost savings as well as other real-world implications associated with the use of biosimilars in clinical practice.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, caution against the ophthalmic use of biosimilar products approved for systemic use. They also review how indications for biosimilars are granted upon approval.